Business
Humacyte Announces Expansion of Intellectual Property for Pipeline Products with Granting of New U.S. Patent for Bioengineered Esophagus
– Patent covers esophagus produced using Humacyte’s proprietary bioengineered regenerative tissue platform, designed for implant in patients with damaged esophagus – – Patent provides coverage into 2041 for the composition of novel bioengineered esophagus – DURHAM, N.C., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced the allowan
About this update from Humacyte, Inc.
[{"type":"image","alt":"Humacyte, Inc","displaySize":"","headline":null,"caption":"Humacyte, Inc","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":57,"url":"https://media.zenfs.com/en/globenewswire.com/6664e34870555953d37f7abc79cd102e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/trBSY4KWXHpBRzQ_5qCqbw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTgwO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/6664e34870555953d37f7abc79cd102e","width":300,"height":57}},"lazy":false},{"type":"text","content":"– Patent covers esophagus produced using Humacyte’s proprietary bioengineered regenerative tissue platform, designed for implant in patients with damaged esophagus –","length":165,"tagName":"p"},{"type":"text","content":"– Patent provides coverage into 2041 for the composition of novel bioengineered esophagus –","length":91,"tagName":"p"},{"type":"text","content":"DURHAM, N.C., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced the allowance of a U.S. Patent covering the composition of a bioengineered esophagus that can be produced using the Company’s proprietary regenerative tissue engineering platform. The patent, titled “Tubular Prostheses (Esophagus),” provides protection into 2041 of key structural and mechanical attributes for its designed use as an esophageal replacement including size, strength, and methods of production. Humacyte’s Tubular Prostheses patent family encompasses composition and methods claims for advanced tissue constructs intended to replace damaged airways, upper digestive, and urinary tracts in patients.","length":844,"tagName":"p"},{"type":"text","content":"“Bioengineered trachea, esophagus, and urinary conduits represent novel treatment programs that target high unmet patient needs as well as highlight the versatility of our regenerative tissue engineering platform and the breadth of our product pipeline,” said Rob Kirkton, Ph.D., Executive Director of New Product and Process Development at Humacyte. With the most recent grant of patent, Humacyte has now secured coverage for composition of matter for bioengineered trachea, esophagus, and urinary conduits in the United States, Europe, Canada, and Australia. Th...